Grünenthal GmbH

Quick facts

Marketed products

• Oxycodone/Naloxone Prolonged Release · Pain Management
  Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed and injected.
• Tapentadol Prolonged Release · Pain Management
  Tapentadol is a mu-opioid receptor agonist and noradrenaline reuptake inhibitor that provides analgesia through dual mechanisms.
• Tapentadol Prolonged Release with Pregabalin
• Topical analgesic · Pain Management
  Topical analgesics work by delivering pain-relieving agents directly to the skin and underlying tissues to reduce localized pain sensation.

Phase 3 pipeline

• CG5503 IR · Pain Management
  CG5503 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.
• Clarithromycin DST (125 mg) · Infectious Disease
  Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
• Clarithromycin DST (187.5 mg) · Infectious Disease
  Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
• Clarithromycin DST (250 mg) · Infectious Disease
  Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
• Clarithromycin Syrup (125 mg) · Infectious Disease
  Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.
• Diclofenac 50 · Pain Management, Rheumatology, Inflammation
  Diclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
• Matching Placebo (twice daily)
  Matching placebo has no active pharmacological mechanism; it is an inert control formulation used in clinical trials.
• Morphine Sulphate Controlled Release · Pain Management
  Morphine sulphate is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and pain relief.
• Placebo Plaster
  Placebo Plaster is an inert transdermal patch formulation designed to serve as a control comparator in clinical trials.
• Progesterone vaginal ring
• RTX-GRT7039 · Pain Management
  RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.
• Tramadol 50 · Pain Management
  Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.
• Tramadol/Diclofenac 25/25 · Pain management
  Tramadol is a centrally acting opioid analgesic, while diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis.
• Tramadol/Diclofenac 50/50 · Pain management
  Tramadol is a centrally acting opioid analgesic, while diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis.

Phase 2 pipeline

• GRT9906 · Pain management
  GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons.

Phase 1 pipeline

• [14C]GRT6019
• GRT0151Y dose escalation
• GRT6019
• GRT7041 MAD
• GRT7041 SAD
• GRT9906 PR tablet
• Lopain · Pain
• Oxycodone API powder
• Oxycodone IR ADF
• Tapentadol Prolonged-release Reference Product
• Tapentadol Test Product 1
• Tapentadol Test Product 2

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Grünenthal GmbH portfolio CI brief
• Grünenthal GmbH pipeline updates RSS